about
Pharmacokinetics of moxalactam in subjects with various degrees of renal dysfunction.Moxalactam and cefazolin: comparative pharmacokinetics in normal subjects.In vitro susceptibility of 104 clinical isolates of Haemophilus influenzae to moxalactam (LY127935), ampicillin, chloramphenicol, and ticarcillinTherapy of obstetrical infections with moxalactam.Tentative interpretive standards for disk susceptibility tests with moxalactam (LY127935).A comparative evaluation of moxalactam: antimicrobial activity, pharmacokinetics, adverse reactions, and clinical efficacy.Comparison of moxalactam and cefazolin as prophylactic antibiotics during cesarean section.Randomized prospective study comparing moxalactam and cefoxitin with or without tobramycin for the treatment of serious surgical infectionsClinical pharmacology of moxalactam in patients with malignant disease.Therapy of lower respiratory tract infections with moxalactam.BRL 17421, a novel beta-lactam antibiotic, highly resistant to beta-lactamases, giving high and prolonged serum levels in humans.Clinical evaluation of moxalactam.Penetration of ocular tissues and fluids by moxalactam in rabbits with staphylococcal endophthalmitis.Clinical experience with Moxalactam in the treatment of pseudomonal and nonpseudomonal infections.Moxalactam in the therapy of serious infectionsDifferences in susceptibilities of species of the Bacteroides fragilis group to several beta-lactam antibiotics: indole production as an indicator of resistance.Renal disposition of moxalactam in experimental animals as revealed by stop-flow analysis.Comparison of moxalactam and gentamicin in the treatment of complicated urinary tract infections.Cefoxitin inactivation by Bacteroides fragilis.Moxalactam therapy of bacterial meningitis in adults.Quality control of moxalactam susceptibility disks.Activity of a new cephalosporin antibiotic, Ro 13-9904 against dense populations of selected enterobacteria.In vitro activity of N-formimidoyl thienamycin, moxalactam, and other new beta-lactam agents against Bacteroides fragilis: contribution of beta-lactamase to resistance.Pharmacokinetics of moxalactam in subjects with normal and impaired renal function.Determination of moxalactam in human body fluids by liquid chromatographic and microbiological methods.Susceptibility of gram-positive cocci to various antibiotics, including cefotaxime, moxalactam, and N-formimidoyl thienamycin.Comparative in vitro activity of new beta-lactam antibiotics against anaerobic bacteria.Comparative in vitro activities of N-formimidoyl thienamycin and moxalactam against nonfermentative aerobic gram-negative rods.In vitro susceptibility of cephalothin-resistant Enterobacteriaceae and Pseudomonas aeruginosa to Amikacin and selected new beta-lactam agents.Clinical evaluation of moxalactam.The third generation cephalosporins.Comparative activities of the oxa-beta-lactam LY127935, cefotaxime, cefoperazone, cefamandole, and ticarcillin against multiply resistant gram-negative bacilli.Activity of beta-lactamase produced by Bacteroides fragilis against newly introduced cephalosporins.Moxalactam (LY127935), a new semisynthetic 1-oxa-beta-lactam antibiotic with remarkable antimicrobial activity: in vitro comparison with cefamandole and tobramycin.GR-20263: a new aminothiazolyl cephalosporin with high activity against Pseudomonas and Enterobacteriaceae.Comparison of moxalactam (LY127935) and cefotaxime against anaerobic bacteria.In vitro activities of moxalactam and cefotaxime against aerobic gram-negative bacilli.Comparison of cefotaxime and moxalactam pharmacokinetics and tissue levels.In vitro activity of N-formimidoyl thienamycin (MK0787).Comparative in vitro activity of moxalactam, cefotaxime, cefoperazone, piperacillin, and aminoglycosides against gram-negative bacilli.
P2860
Q30450692-F73F6B8D-405E-41E4-93B1-CFA86786BC2EQ30451388-6A7D0FE4-D9A6-41E4-AE8B-3C4C22866DF7Q33725629-0B1A9D30-FEEF-4C6C-97C3-7577C0B0CCCCQ33730322-81C8E534-8394-4160-805E-E82709DF1284Q33735948-0FDFDEC9-7D9B-4549-9E85-EA0C345A93E4Q34707883-73A0A436-17F8-40FB-92DD-3A17FBB8D1B5Q35570483-110BE34D-8C94-4465-B817-85A454DFEDB7Q35573250-5EF2D242-D18C-47D4-BFEC-A97411FCFB45Q35669389-ACD49552-27C0-4795-8049-B652DB922781Q35669739-5AB43D7F-6D52-4FBC-8D7E-7962363AD642Q35670880-A2FD65DA-AF07-41B9-A467-9026EB00378FQ35670939-C9A78928-7A1C-4059-802F-899B41AC92E1Q35671978-BB2A9959-E981-41D0-AA96-80AD9356403EQ35674991-7EF717E1-9FF8-4713-896B-13C9DD16A6FEQ35675249-2273B334-CC2D-424E-8EE2-0FE463329CC5Q35718303-63BB3E60-31ED-46F5-B0CB-6AC31DBE8A5EQ35739654-CD228C11-D823-4655-9F79-F2D934306AD2Q35754903-BA81A61B-7CCB-4EDE-9909-D53CA9DB1FEFQ35755796-AE0042AA-412D-4124-8DF2-8EFDEF157DD3Q35770003-0AF5830D-E0C1-4631-BE43-4B51D0AD6679Q37308010-3DE40DCF-B3DF-43A8-A4FF-362922DD4CEFQ39854371-4A6D42D7-86E3-42A2-936E-79E9EED9FBFCQ39854523-C1ECA06B-C97F-4B7E-828D-5E9610D3398AQ39855256-8C41A6C9-895E-4CF7-8682-921ABDC07F64Q39855613-B54B026C-3831-469F-BEC1-424752D44106Q39855945-E3FD7DFE-93E1-41B5-A39A-B8CE8BB9DF00Q39856001-D4623D8B-416B-48CD-B309-DF12A9CCC7B1Q39856904-5045B20A-F286-4C19-8BB2-AE0BDB9B428DQ39857062-976089FB-ABCB-4E39-971F-6656EE73BCBFQ39857079-EB1F2761-F901-442F-9790-CD1E0676B64EQ40253708-8148B7ED-2367-4347-A3F2-DC6EB8A8E0D2Q40281490-020CDE48-38DD-4C3B-93CE-5B6442F04B90Q40281964-ACE555DB-E629-4646-9EB1-E4D861A51EDDQ40281987-9ABEB920-968A-486A-8666-89AA79177F88Q40282054-9A9C01DC-AF62-463B-8889-BB6B43B533F2Q40282147-CF44206A-C7F7-4D34-ACAC-B6D6A4503DB2Q40282202-897319EC-28F3-420C-9876-46819DEBAC30Q40282760-91D1C876-CA68-42A5-8F37-0F7FEEA7BD5EQ40283004-995F89D1-181E-49A3-821F-778B41A5552BQ40283012-E99AF52D-51CA-485B-A345-12E7EB200579
P2860
description
1979 nî lūn-bûn
@nan
1979年の論文
@ja
1979年論文
@yue
1979年論文
@zh-hant
1979年論文
@zh-hk
1979年論文
@zh-mo
1979年論文
@zh-tw
1979年论文
@wuu
1979年论文
@zh
1979年论文
@zh-cn
name
In vitro activity of LY127935.
@en
type
label
In vitro activity of LY127935.
@en
prefLabel
In vitro activity of LY127935.
@en
P2093
P2860
P356
P1476
In vitro activity of LY127935.
@en
P2093
P2860
P304
P356
10.1128/AAC.16.3.287
P407
P577
1979-09-01T00:00:00Z